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Background: Intrahepatic cholestasis of pregnancy (ICP) is a cholestasis condition caused by elevated levels of
serum bile acids that mainly occurs in the third trimester of pregnancy. Maternal symptoms include pruritus;
elevation of transaminases, biliary enzymes, and bilirubin levels; and abnormal liver function tests. Fetal symptoms
include spontaneous preterm labor, fetal distress, and intrauterine death. It is more prevalent in the Caucasians and
is rarely found in Asian countries, including Japan. The etiology of ICP has been reported as involving various
factors such as, environmental factors, hormone balance, and genetic components. The genetic factors include
single-nucleotide polymorphisms (SNPs) in the genes of canalicular transporters, including ABCB4 and ABCB11. It has
also been reported that the combination of these SNPs induces severe cholestasis and liver dysfunction.
Case presentation: Here, we report for the first time a 24-year Japanese case of severe ICP diagnosed by
typical symptoms, serum biochemical analysis, and treated with the administration of ursodeoxycholic acid which
improved cholestasis and liver injury and prevented fetal death. The sequence analysis showed SNPs reported their
association with ICP in the ABCB11 (rs2287622, V444A) and ABCB4 (rs1202283, N168N) loci.
Conclusion: The risk of ICP has been reported to be population-specific, and it is rare in the Japanese population.
Our case was successfully treated with ursodeoxycholic acid and the genetic sequence analysis has supported the
diagnosis. Because genetic variation in ABCB4 and ABCB11 has also been reported in the Japanese population, we
need to be aware of potential ICP cases in pregnant Japanese women although further studies are necessary.
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The etiology of intrahepatic cholestasis of pregnancy
(ICP) involves various factors such as environmental fac-
tors, hormonal balance, and genetic components. The
relation of the genetic factors lead to the various preva-
lence rates among different ethnic groups. It has been
reported that the prevalence in Caucasians in Europe,* Correspondence: kenya-k@med.niigata-u.ac.jp
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to 1.5% [1]. On the other hand, much fewer number of
cases have been reported in Asian countries [2]. Symp-
toms include itching, particularly of the palms and feet,
and jaundice. Fetal consequences of ICP include spon-
taneous preterm labor, fetal distress, and intrauterine
death due to increased levels of serum bile acids [1-5].
Biochemical analysis shows a mild increase in transami-
nases, bilirubin, other biliary enzymes, and serum bile
acids levels of >10 μmol/L [6,7]. In addition, the level of
cytotoxic bile acids, such as chenodeoxycholic acid,
increases 10-100 times higher than the normal level.tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Results of laboratory investigation
Hematology Biochemistry
WBC 10,080 /μl TP 6.8 g/dl TG 197 mg/dl
RBC 410x104 /μl Alb 3.7 g/dl TC 191 mg/dl
Hb 13.3 g/dl BUN 8 mg/dl IgG 908 mg/dl
Ht 39.8% Cre 0.36 mg/dl CRP 0.05 mg/dl
PLT 25.5x104 /μl T-Bil 6.3 mg/dl Bile acid 89.6 μmol/l
D-Bil 4.0 mg/dl C/BA 0.24
Coagulation AST 264 IU/l HbA1c 4.2%
PT% 121% ALT 545 IU/l Serum Marker
ALP 310 IU/l AFP 36 ng/ml
LDH 241 IU/l AFP-L3 32.8%
γ-GTP 14 IU/l PIVKAII 44 mAU/ml
ChE 137 IU/l ANA (-)
AMA (-)
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however, recently, reviews have reported that ICP is also
related to an increased risk of developing hepatobiliary
diseases later in life [8]. More recently, results of com-
prehensive analysis of genetic variation in ICP have been
reported, and common variations around ABCB4 and
ABCB11 encoding multidrug resistance protein 3 (MDR3)
and bile salt export pump (BSEP), respectively, have been
reported as key factors [1,6]. Similar results have been
reported that ABCB4 [9-13] and ABCB11 [14] have
significant relationships with the etiology of ICP. The
combination of these mutations has been reported to be
related to severe ICP. For example, the combination of
homozygous polymorphisms in ABCB11 at the comple-
mentary DNA position 1331 with a thymine replaced by a
cytosine (1331 T > C, rs2287622), leading to an exchange
from valine to alanine (V444A), and in ABCB4 at position
959 in exon 9 with a cytosine replaced by a thymine
(959 C > T), leading to an exchange of serine to pheny-
lalanine (S320F), and some other synonymous SNPs are
considered to be related to the etiology of severe type of
ICP [15]. Further analysis has shown that the association
of 1331 T > C (rs2287622) was also driven by other SNP
(rs3815676) [1]. Therefore, these genetic variations may
contribute to the difference of the occurrence in ethnic
groups and further studies will clarify the more accurate
contributions of each variation, since these SNPs have also
been found in general population [16-18]. Here, we report
the first case of a Japanese woman diagnosed with ICP
based on severe pruritis, increased levels of bile acid and
hepatobiliary enzymes, and successfully treated with
ursodeoxycholic acid (UDCA) preventing fetal death and
clinical symptoms as well. The genetic sequence analysis
showed a homozygous polymorphism in ABCB11 at
1331 T > C leading to V444A that is often reported in the
conditions [1,15]. Furthermore, another synonymous
single-nucleotide polymorphism in ABCB4 (504 C > T,
rs1202283, N168N) was combined in our patient that have
never been reported the association with this disease.
Based on these results, we concluded our case as a first
Japanese case of severe ICP with mutations in ABCB11
and ABCB4. Further study will help us to find and appro-
priately treat patients preventing fetal death and clinical
symptoms.
Case presentation
A 24-year-old Japanese pregnant female presented with
severe pruritis and jaundice in the 15th week of her first
pregnancy and was referred to our department. She
had never been diagnosed with a constitutional hyper-
bilirubinemia. Physical examination revealed skin and
conjunctival jaundice. No nausea, vomiting, headache,
or fatigue were noted, and her blood pressure and
other physiological tests were normal. Laboratory testsrevealed the increased levels of direct bilirubin (D-Bil,
4.0 mg/dl), aspartate aminotransferase (AST, 264 IU/l),
alanine aminotransferase (ALT, 545 IU/l), and lactate de-
hydrogenase (LDH, 241 IU/l). Total bile acid level was
high (89.6 μmol/l), and the ratio of the cytotoxic cheno-
deoxycholic acid to total bile acid (C/BA) was 0.24 at the
time of admission (Table 1). No hemolysis or decrease in
platelet count was observed, and tests for viral mar-
kers including hepatitis A, B, and C and autoimmune
markers including anti-nuclear, anti-mitochondrial, and
anti-phospholipid antibodies were negative. Slight increa-
ses in AFP (α-fetoprotein) to 36 ng/ml and AFP-L3
(Lens culinaris agglutinin -reactive α-fetoprotein isoform)
to 32.8%, which are often found in pregnancy were
detected and protein induced by Vitamin K absence or
antagonists-II (PIVKAII) showed normal level (Table 1).
No proteinuria or ketonuria was noted on urine tests.
Ultrasonography revealed no chronic damage or acute
fatty infiltration in the liver. Computed tomography was
not utilized due to the pregnancy. The patient’s mother
had a history of third-trimester pruritis; however, her
symptoms were milder, and she had no history of fetal
death or preterm delivery. No symptoms were marked in
her grandmother. Based on these findings, she was diag-
nosed with ICP with severe clinical symptoms, although
rare in the Japanese population. To support the diagnosis,
we obtained the patient’s written informed consent and
performed genomic sequencing of genes such as ABCB4
and ABCB11, the genetic variations of which have been
reported to be related to the etiology and severity of the
disease (approved by the ethics committee at the Niigata
University, No. 536). Sequencing of all the coding exons
of the genes revealed a nonsynonymous homozygous
mutation in ABCB11 and a synonymous mutation in
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ABCB11 was a major single-nucleotide exchange from
thymine to cytosine at the position 1331 (1331 T > C),
leading to an exchange from valine to alanine (V444A).
This has been reported to be strongly associated with ICP
based on a large cohort study [1]. The synonymous muta-
tion in ABCB4 was 504 C > T, which has never been re-
ported to be association with the disease.Clinical course
After the diagnosis of ICP, the patient was treated with
UDCA (300 mg daily) from the 18th day of her admission
and the dose was increased to 600 mg daily at 13 weeks
after the admission since the level of ALT showed mild in-
creasing pattern (Figure 2). Her pruritis slowly improved,
and D-Bil, AST, ALT, and LDH levels slowly decreased to
normal ranges after the initiation of the administration of
UDCA and returned to the normal levels of 0.6 mg/dl,
17 IU/l, 20 IU/l, and 135 IU/l, respectively within 3 weeks
after the spontaneous preterm delivery of a healthy and
well-developed infant at the 35th week of gestation
(Figure 2). Her C/BA ratio decreased to 0.19 (total bile
acid level of 270.3 μmol/l) within 12 weeks and returned
to the minimum level of 0.02 (total bile acid level of
42.5 μmol/l) just after delivery. The administration of
UDCA was discontinued 3 weeks after delivery, and no
symptom recurrence or increases in the level of hepato-
biliary enzymes were observed.Figure 1 Single-nucleotide polymorphisms in ABCB11 and ABCB4 of t
was performed with the standard genomic sequencing procedure. Black ar
from the database is shown in the upper panel.Discussion
Viral hepatitis, autoimmune liver injury, hyperemesis
gravidarum, acute fatty liver of pregnancy, HELLP
(hemolysis, elevated liver enzyme levels, and low platelet
levels) syndrome, preeclampsia, and ICP are known to be
involved in the etiology of liver injury found during preg-
nancy [1,6]. Among these diseases, ICP is frequently found
in Caucasians, and the difference in the prevalence rate of
ICP among the populations is due to genetic variation in
the genes encoding ATP-Binding Cassette (ABC) trans-
porters [2]. The most common symptom is pruritis, which
typically presents in the third trimester of pregnancy, but
early disease onset can be observed in ~20% of cases [7].
Symptoms disappear after delivery; however, it has been
reported that ICP is associated with an increased risk of
developing various hepatobiliary diseases, including gall-
stones and cirrhosis, later in life [8]. Biochemical analysis
revealed increased levels of transaminases, bilirubin, and
serum bile acids (>10 μmol/l). However, clinical jaundice
is detected in 10%-15% of patients, and bile acid levels
rarely exceed 100 μmol/l [2,5]. The symptoms and the
level of serum enzymes ranged variously, and the severe
type was reported with an early onset, severe pruritis, sig-
nificant elevation of the hepatobiliary enzymes [15].
Recent large cohort studies and reviews reported that
common variations around ABCB4 and ABCB11 as key
factors for developing ICP [1-6]. In addition, it has been
reported that the SNP in ABCB11 (1331 T > C), leading
to an exchange from valine to alanine (V444A), is relatedhe patient. Sequencing of all the coding exons of ABCB4 and ABCB11
rows indicate the mutations found in the patient. Genetic information
Figure 2 Clinical course of the patient. The time-dependent levels of AST, ALT, and T-Bil are shown in the upper panel. The gray bar indicates the
ratio of chenodeoxycholic acid in bile acid (C/BA ratio), and the black line in the lower panel indicates the total bile acid level. Ursodeoxycholic acid, U;
Chenodeoxycholic acid, C; Bile acid, C/BA.
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might affect the expression of transporters and their
structures that transport sulphated progesterone meta-
bolites which significantly increases during pregnancy
leading to the clinical symptoms [19]. Our case showed
significant pruritis and increased levels of total and cyto-
toxic bile acids at the time of admission that was first
trimester of pregnancy. Her serum markers showed no
evidence of other hepatic diseases, such as HELLP
syndrome, acute fatty liver of pregnancy, autoimmune
liver diseases, or viral chronic hepatitis. The major SNP
in ABCB11 (1331 T > C, rs2287622) and the additional
synonymous mutation in ABCB4 (504 C > T, rs1202283)
were confirmed by the genomic sequencing strategy.
These results are indicating the potential relationship
with the disease [14] and its severity [15], however since
these variations have also been found in general popula-
tion [16-18], the diagnosis of the disease based on the
clinical symptoms and exclusion of other liver diseases
like our case. Although a standard therapeutic method
has not been established, two recent studies encouraged
the administration of UDCA for ICP to reduce pruritis
and improve hepatobiliary enzyme levels to reduce the
risk of fetal death [20,21]. The therapeutic effect of
UDCA has been reported from various aspects. It re-
places cytotoxic bile acid, such as chenodeoxycholic acid
into UDCA, directly. In addition, it increases the mem-
brane transport expression, such as MDR3 and BSEP,
leading to the stimulation of hepatobiliary excretion of
progesterone disulphates that ameliorate pruritus and
liver injury [19]. These effects contribute for the treat-
ment of ICP [20,21]. In our case, UDCA was effective
for improving symptoms, i.e., led to decreases in levelsof hepatobiliary enzymes and the C/BA ratio, and pre-
vented intrauterine death and meconium passage. The
C/BA ratio was used to define the level of bile acid to-
xicity because the total bile acid level increased after the
administration of UDCA followed by replacement with
cytotoxic chenodeoxycholic acid. Further studies will
help the understandings and the genetic diagnosis, be-
cause no need exists to perform liver biopsy as an inter-
ventional method to diagnose the disease. In addition,
as it is also known that ICP recurs in subsequent preg-
nancy [2], it is important to be aware of the disease and
its therapeutic options.Conclusion
The risk of ICP has been reported to be population-
specific, and it is rare in the Japanese population. Here,
we report the first Japanese case of ICP with severe
symptoms and successfully treated with UDCA. The
genetic sequence analysis also supported the diagnosis.
Because genetic variation in ABCB4 and ABCB11 has
also been reported in the Japanese population, we need
to be aware of potential ICP cases in pregnant Japanese
women although further studies are necessary.Consent
Written informed consent was obtained from the patient
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